MA54464A - Anticorps humanisé anti-récepteur de l'igf-i - Google Patents

Anticorps humanisé anti-récepteur de l'igf-i

Info

Publication number
MA54464A
MA54464A MA054464A MA54464A MA54464A MA 54464 A MA54464 A MA 54464A MA 054464 A MA054464 A MA 054464A MA 54464 A MA54464 A MA 54464A MA 54464 A MA54464 A MA 54464A
Authority
MA
Morocco
Prior art keywords
igf
humanized anti
receptor antibody
antibody
receptor
Prior art date
Application number
MA054464A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Hirofumi Higuchi
Daisuke Ishikawa
Hirotsugu Kato
Naoko Namiki
Masayo Ohori
Kenichiro Takagi
Tomoyo Takeo
Akira Tanokura
Satoshi Yamamura
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MA54464A publication Critical patent/MA54464A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA054464A 2018-12-03 2019-12-02 Anticorps humanisé anti-récepteur de l'igf-i MA54464A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018226669 2018-12-03

Publications (1)

Publication Number Publication Date
MA54464A true MA54464A (fr) 2021-10-20

Family

ID=70974206

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054464A MA54464A (fr) 2018-12-03 2019-12-02 Anticorps humanisé anti-récepteur de l'igf-i

Country Status (19)

Country Link
US (1) US12227563B2 (fr)
EP (1) EP3895732A4 (fr)
JP (2) JP7246409B2 (fr)
KR (1) KR102771846B1 (fr)
CN (1) CN113286612B (fr)
AR (1) AR117673A1 (fr)
AU (1) AU2019393487A1 (fr)
BR (1) BR112021010479A2 (fr)
CL (1) CL2021001446A1 (fr)
CO (1) CO2021007229A2 (fr)
IL (1) IL283099B2 (fr)
MA (1) MA54464A (fr)
MX (1) MX2021006495A (fr)
MY (1) MY205006A (fr)
PH (1) PH12021551210A1 (fr)
SG (1) SG11202105714UA (fr)
TW (1) TWI850288B (fr)
WO (1) WO2020116398A1 (fr)
ZA (1) ZA202103350B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296519A (en) * 2020-06-02 2022-11-01 Teijin Pharma Ltd Anti-igf-1 receptor humanized antibody
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2796468A2 (fr) 2001-01-05 2014-10-29 Pfizer Inc Anticorps contre le récepteur du facteur de croissance 1 analogue à l'insuline
KR20050021001A (ko) * 2002-06-14 2005-03-04 이뮤노젠 아이엔씨 인간 인슐린-유사 성장인자-i 수용체 항체
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
WO2008079849A2 (fr) * 2006-12-22 2008-07-03 Genentech, Inc. Anticorps liés au récepteur du facteur de croissance semblable à l'insuline
RU2010144014A (ru) 2008-04-03 2012-05-27 Ф. Хоффманн-Ля Рош Аг (Ch) Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств
AR105553A1 (es) * 2015-04-27 2017-10-18 Pf Medicament Anticuerpo del receptor del factor 1 del crecimiento similar a insulina (igf-1r) y su utilización para diagnosticar cáncer
JP6096267B1 (ja) 2015-12-09 2017-03-15 上銀科技股▲分▼有限公司 ボールねじに用いる防塵ユニット
CN110691794B (zh) * 2017-05-30 2023-10-27 帝人制药株式会社 抗igf-i受体抗体

Also Published As

Publication number Publication date
TWI850288B (zh) 2024-08-01
MY205006A (en) 2024-09-27
CN113286612A (zh) 2021-08-20
PH12021551210A1 (en) 2021-11-08
IL283099B1 (en) 2024-10-01
US12227563B2 (en) 2025-02-18
ZA202103350B (en) 2022-08-31
IL283099A (en) 2021-06-30
SG11202105714UA (en) 2021-06-29
EP3895732A4 (fr) 2022-09-14
TW202039559A (zh) 2020-11-01
US20220033485A1 (en) 2022-02-03
CL2021001446A1 (es) 2022-01-14
CA3120740A1 (fr) 2020-06-11
CN113286612B (zh) 2024-12-24
JP2023011808A (ja) 2023-01-24
AR117673A1 (es) 2021-08-25
MX2021006495A (es) 2021-07-06
KR20210088625A (ko) 2021-07-14
CO2021007229A2 (es) 2021-08-19
KR102771846B1 (ko) 2025-02-21
JP7246409B2 (ja) 2023-03-27
WO2020116398A1 (fr) 2020-06-11
EP3895732A1 (fr) 2021-10-20
AU2019393487A1 (en) 2021-06-03
IL283099B2 (en) 2025-02-01
BR112021010479A2 (pt) 2021-11-16
JPWO2020116398A1 (ja) 2021-09-30

Similar Documents

Publication Publication Date Title
MA54464A (fr) Anticorps humanisé anti-récepteur de l'igf-i
IL270971A (en) Antibody against the 1-IGF receptor
MA52742A (fr) Anticorps bispécifiques dll3-cd3
EP4159860A4 (fr) Anticorps humanisé de récepteur anti-igf-1
EP3765522A4 (fr) Anticorps anti-claudine 18.2
MA52212A (fr) Anticorps multivalent
LT3762380T (lt) Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai
EP3784699A4 (fr) Anticorps anti-tl1a optimisés
IL281428A (en) Chimeric antigen receptor
EP4017883A4 (fr) Nouveaux anticorps anti-cldn18.2
MA49990A (fr) Récepteurs de liaison à l'antigène améliorés
EP3938401A4 (fr) Récepteurs d'antigènes chimériques anti-bcma
IL276836A (en) Cd83-binding chimeric antigen receptors
EP3860977A4 (fr) Antagonistes de l'intégrine
EP3752536A4 (fr) Anticorps anti-her2
EP4032907A4 (fr) Anticorps et récepteur antigénique chimérique ciblant bcma
IL289899A (en) Anti-hk2 chimeric antigen receptor (car)
MA51903A (fr) Formulations d'anticorps b7-h4
EP3806903A4 (fr) Récepteurs antigéniques chimériques anti-cd79a
IL284807A (en) Antibodies specific to human nectin-2
EP3703680A4 (fr) Antagonistes du récepteur muscarinique m4 à l'acétylcholine
EP3746421A4 (fr) Antagonistes du récepteur muscarinique de l'acétylcholine m4
MA53218A (fr) Antagonistes de l'intégrine
EP3926410A4 (fr) Dispositif de formation d'image
MA51902A (fr) Schémas posologiques d'anticorps b7-h4